Advertisement

Lexington-based biotech RainDance Technologies Inc., just months after closing on a large financing round, has landed a pair of deals for its microdroplet-based tools to be used in genetic screening systems, one with California-based Ambry Genetics and the second with a division of Roche Group.

RainDance did not release financial details for either deal. Both of them involve developing a new sequencing platform for “simple and cost-effective investigation of drug absorption, distribution, metabolism, and excretion (ADME).” The intent is to be able to identify adverse drug reactions to reduce the instances and the cost of hospitalization associated with such events, officials said.

SOURCE

Advertisement
Advertisement